Completed PHASE1 INTERVENTIONAL 8-arm NCT00813670

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects

Sponsor: Xenon Pharmaceuticals Inc.

Conditions Healthy Human Volunteers

Interventions XPF-001

Updated 5 times since 2017 Last updated: Sep 10, 2009 Started: Nov 30, 2008 Primary completion: May 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Human Volunteers, this trial is completed. The trial is conducted by Xenon Pharmaceuticals Inc. and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xenon Pharmaceuticals Inc.

Data source: Xenon Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada